Fort Worth Cancer Specialist Explains How New Skin Cancer Treatment Fights Killer Melanoma

Share Article

Fort Worth cancer specialist describes how new skin cancer treatment drug, Yervoy, targets melanoma that has spread to other parts of the body. The drug recently received approval from the U. S. Food & Drug Administration (FDA).

“Recent FDA approval of Yervoy, a new skin cancer treatment drug using the body’s defenses to fight melanoma, is great news,” said Bibas Reddy, D.O, Fort Worth cancer specialist, (http://www.thecentertx.com/physicians_reddy.html).

“To make it very simple, it is believed that Yervoy helps the body understand melanoma cells are heading toward it, then tells the body to respond. It acts like a coach telling the body to pick up a baseball bat and hit the cancer ball out of the park. It is not a cure, but it keeps us moving in a winning direction—giving patients hope where we had little before,” said Reddy.

Clinical trials showed Yervoy increased survival from 6.5 months to 10 months. With approval from the U.S. Food & Drug Administration (FDA), patients will have now have access to the drug at local cancer centers.

According to the FDA, melanoma is the leading cause of death from skin disease. An estimated 68,130 new cases of melanoma were diagnosed in the United States during 2010 and about 8,700 people died from the disease, according to the National Cancer Institute.

Dr. Reddy is a board certified medical oncologist affiliated with The Center for Cancer & Blood Disorders at the Fort Worth central campus location (http://www.thecentertx.com). The center offers world-class cancer treatment with healing focused on a patient’s entire life—physical, emotional and spiritual. Eighteen physicians and a staff of ninety medical and administrative professionals provide cancer treatment to more than 6,000 patients annually at ten clinic locations: Fort Worth (three sites), Arlington, Weatherford, Burleson, Cleburne, Mineral Wells, Granbury and Stephenville.

###

Share article on social media or email:

View article via:

Pdf Print